pharma · Pulmonary Embolism · Carcinoma, Hepatocellular
Bayer HealthCare Animal
Bayer HealthCare AG
Bayer HealthCare AG is a pharma organization headquartered in EU. Primary therapeutic focus areas include Pulmonary Embolism, Carcinoma, Hepatocellular, Colorectal Neoplasms, Macular Edema, Prevention of Ischemic Stroke.
3915 S 48TH STREET TER, St. Joseph, Missouri 64503, us HQ
1919 Founded
8 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 3915 S 48TH STREET TER, St. Joseph, Missouri 64503, us
- Founded
- 1919
- Employees
- 8
- Programs
- 34
- Drugs
- 32
- Patents
- 24
Asundexian (BAY2433334)
Phase 3 · small molecule · Prevention of Stroke or Systemic Embolism
Asundexian (BAY2433334) for Prevention of Stroke or Systemic Embolism is a Phase 3 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).
Internal code 19767
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Bayer HealthCare AG
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Prevention of Stroke or Systemic Embolism
- Status
- terminated
- Trials
- 1